Articles

The ELEVATE study highlights elacestrant-based combinations as a promising all-oral treatment strategy to overcome resistance and improve outcomes in estrogen receptor–positive/HER2-negative metastatic breast cancer. Read More ›

The INSEMA trial reveals how axillary surgery and radiotherapy techniques influence dose distribution and regional nodal irradiation in patients with early breast cancer undergoing breast-conserving surgery. Read More ›

The INSEMA trial explores the safety and benefits of sentinel lymph node biopsy omission versus completion axillary lymph node dissection in patients with early breast cancer undergoing breast-conserving surgery. Read More ›

The LORETTA trial evaluates tamoxifen monotherapy as a potential nonsurgical option for carefully selected patients with low-risk, estrogen receptor–positive/HER2-negative ductal carcinoma in situ. Read More ›

Discover how combining preoperative radiation with immunotherapy is revolutionizing treatment for high-risk, HR-positive/HER2-negative breast cancer in a groundbreaking clinical trial. Read More ›

New research reveals that preoperative breast MRI may not improve outcomes for early-stage breast cancer patients, challenging its routine use in surgical planning. Read More ›

New insights reveal patient preferences for oral endocrine therapy over intramuscular options in metastatic breast cancer, emphasizing the need for personalized treatment decisions. Read More ›

New research highlights critical gaps in ESR1 mutation testing for estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer, emphasizing the need for increased use of blood-based circulating tumor DNA methods to improve treatment outcomes. Read More ›

The ADELA trial investigates the potential of combining elacestrant with everolimus to overcome resistance and improve outcomes in ESR1-mutated, estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. Read More ›

Discover the latest breakthroughs in breast cancer treatment, as innovative strategies to overcome resistance to CDK inhibitors are explored, and new therapeutic possibilities are unlocked. Read More ›